English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The use of psychostimulants, particularly methylphenidate, to treat Attention Deficit/Hyperactivity Disorder (ADHD) symptoms in children and adolescents has increased rapidly since the 1990s (Schubert et al. 2010). In the 2000s serious reports on cardiovascular adverse drug reactions (ADRs), sudden deaths and psychiatric disorders have led the regulatory agencies in Europe and the United States (US) to warn against use of psychostimulants in the paediatric population (Schubert et al., 2010). In July 2007, class labels were implemented in the product information to reflect more specific information about cardiovascular and psychiatric adverse events and long-term suppression of growth (European Medicines Agency, 2007, US Food and Drug Administration, 2007). Despite these warnings, the number of children treated as well as the amount of psychostimulants prescribed per child has steadily increased (Kalverdijk et al., 2008).

Trends in the Prescribing and Adverse Drug Reactions Patterns of Psychostimulants Among Danish Children and Adolescents